Terremoto Biosciences

Executive Summary

Terremoto Biosciences is a clinical-stage biotechnology company pioneering a novel class of small-molecule therapeutics that leverage advanced covalent chemistry to target lysine residues. This approach aims to address historically 'undruggable' targets in oncology and genetic diseases, offering the potential for superior efficacy and safety compared to conventional therapies. Founded in 2021 and headquartered in San Diego, the company is privately held and has not disclosed its total funding or valuation. Its proprietary platform enables precision targeting of lysine residues, which could expand the druggable proteome and unlock new treatment paradigms for patients with limited options.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead program60% success
• Q1 2026Initial preclinical proof-of-concept data70% success
• TBDSeries A or B financing round50% success